{"filing":{"accession_number":"0001178913-26-003510","cik":"0001638097","ticker":"ENTX","company_name":"Entera Bio Ltd.","form":"8-K","filing_date":"2026-07-16","report_date":null,"primary_document":"zk2635691.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1638097/000117891326003510/zk2635691.htm"},"events":[{"id":18406,"run_id":16545,"accession_number":"0001178913-26-003510","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Entera Bio held its 2026 Annual Meeting of Shareholders on July 14, 2026, with voting results disclosed covering ten proposals including director elections (Sean Ellis, Steven D. Rubin, Geno H. Germano), executive and director compensation approvals, equity plan amendments, and auditor ratification.","company_name":"Entera Bio Ltd.","ticker":"ENTX","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17209,"accession_number":"0001178913-26-003510","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final voting results from Entera Bio's 2026 Annual Meeting of Shareholders held on July 14, 2026, covering ten proposals including director elections (Sean Ellis, Steven D. Rubin, Geno H. Germano), executive and director compensation approvals, equity plan amendments, and auditor ratification. The comprehensive tabulation of votes for and against each proposal is the hallmark of shareholder_vote_results classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:09:08.031557+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":18407,"run_id":16545,"accession_number":"0001178913-26-003510","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Shareholders approved an amendment to the 2018 Equity Incentive Plan increasing the share pool by 2,500,000 ordinary shares, expanding the equity available for compensatory grants to officers and directors.","company_name":"Entera Bio Ltd.","ticker":"ENTX","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17207,"accession_number":"0001178913-26-003510","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports shareholder approval of an amendment to the 2018 Equity Incentive Plan increasing the share pool by 2,500,000 ordinary shares. This is a compensatory arrangement amendment affecting equity grants available to officers and directors, fitting the exec_compensation category. The material increase in authorized equity for incentive purposes would affect investor assessment of dilution and compensation capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:09:08.031557+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":18408,"run_id":16545,"accession_number":"0001178913-26-003510","anchor_item_number":"5.03","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"summary":"Shareholders approved an amendment to the Articles of Association increasing authorized ordinary shares from 140,010,000 to 350,000,000, a routine administrative authorization of capital structure.","company_name":"Entera Bio Ltd.","ticker":"ENTX","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17208,"accession_number":"0001178913-26-003510","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure reports a shareholder-approved amendment to the Articles of Association increasing authorized ordinary shares from 140,010,000 to 350,000,000. While a governance matter, this is a routine administrative amendment to capital structure authorization that does not itself constitute a material event affecting investor assessment—it is a procedural authorization that enables future issuances but does not commit the company to any specific dilutive action or material transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:09:08.031557+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17207,"accession_number":"0001178913-26-003510","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports shareholder approval of an amendment to the 2018 Equity Incentive Plan increasing the share pool by 2,500,000 ordinary shares. This is a compensatory arrangement amendment affecting equity grants available to officers and directors, fitting the exec_compensation category. The material increase in authorized equity for incentive purposes would affect investor assessment of dilution and compensation capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:09:08.031557+00:00","company_name":"Entera Bio Ltd.","ticker":"ENTX","filing_date":"2026-07-16"},{"id":17208,"accession_number":"0001178913-26-003510","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"This disclosure reports a shareholder-approved amendment to the Articles of Association increasing authorized ordinary shares from 140,010,000 to 350,000,000. While a governance matter, this is a routine administrative amendment to capital structure authorization that does not itself constitute a material event affecting investor assessment—it is a procedural authorization that enables future issuances but does not commit the company to any specific dilutive action or material transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:09:08.031557+00:00","company_name":"Entera Bio Ltd.","ticker":"ENTX","filing_date":"2026-07-16"},{"id":17209,"accession_number":"0001178913-26-003510","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final voting results from Entera Bio's 2026 Annual Meeting of Shareholders held on July 14, 2026, covering ten proposals including director elections (Sean Ellis, Steven D. Rubin, Geno H. Germano), executive and director compensation approvals, equity plan amendments, and auditor ratification. The comprehensive tabulation of votes for and against each proposal is the hallmark of shareholder_vote_results classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T20:09:08.031557+00:00","company_name":"Entera Bio Ltd.","ticker":"ENTX","filing_date":"2026-07-16"}]}